Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
A recent neutron analysis of glaucoma drugs and their interaction with human carbonic anhydrase II (hCA II) enzyme revealed the impact of temperature, pH, and electrical charge on drug targeting. The study provides new information about hydrogen-bonding networks in hCA II, which may aid in designing more effective cancer treatments.
Researchers at Cold Spring Harbor Laboratory have discovered that a widely-studied cancer gene called MELK does not play a crucial role in cancer cell growth. The team's findings suggest that inherent flaws in scientific techniques used to link MELK to cancer led to the error.
Combining a blood test for high alpha fetoprotein (AFP) levels with ultrasound imaging improves liver cancer detection by 40 percent, according to researchers at UT Southwestern Medical Center. Early detection is crucial for improving survival rates in patients with liver cancer, which is on the rise in the US.
A multidisciplinary team of Penn researchers will investigate immune system response to cancers and develop new therapies for gynecologic cancers. The team will examine how patients vary in their responses to different anti-cancer therapies and identify key factors contributing to treatment success.
A phase 3 clinical trial showed apalutamide treatment significantly delayed metastasis development in men with prostate cancer resistant to standard therapy. The treatment also improved survival and reduced disease progression symptoms.
Researchers at UPMC Hillman Cancer Center have identified a new genetic change in the estrogen receptor that contributes to therapy resistance in ER-positive breast cancer. The presence of ESR1 fusion proteins in treatment-resistant breast cancer may lead to improved treatments for this form of the disease.
A global study found that treating multiple chronic diseases is putting a significant financial burden on countries' health systems and individuals. Patients with multimorbidity often face high out-of-pocket costs, leading to non-adherence to prescribed medicines.
Researchers at Boston University School of Medicine have found that individual BET bromodomain proteins work independently, reducing the effectiveness of pan-BET inhibitors. This discovery paves the way for more fine-tuned experiments and treatments in breast cancer patients with varying levels of protein expression.
Researchers at Hong Kong Baptist University have designed and synthesized a smart globular macromolecular machine vehicle for actively controlled cancer drug delivery, enhancing the efficacy of targeted therapy drugs. The breakthrough offers insights into targeted therapies such as Chlorambucil in leukemia treatment.
Researchers have developed a new method to grow patient-derived xenografts (PDX) liver cancer cells in culture, which maintains their proper shape and function and grows as organoids. The success of the engineered organoids has the potential to revolutionize the screening and development of liver cancer drugs.
A team of computer scientists has developed a new system to rapidly determine which cancer drugs are likely to work best given a patient's genetic markers. eGARD, the first publicly available system of its kind, can match genetic signatures with outcomes with 95 percent precision.
Researchers at H. Lee Moffitt Cancer Center identified a new target to reduce the risk of graft-versus-host disease (GVHD) in stem cell transplants. The JAK2 inhibitor pacritinib has been shown to minimize GVHD while maintaining antitumor response.
Researchers have found that the loss of a tumor suppressor in triple-negative breast cancer provides clues for novel treatments. Drugs targeting PLK1, AURK and CHK1 may be effective for 20-30% of patients with RB-deficient tumors.
Researchers at Arizona State University have discovered that ibrutinib can also target ERBB4, a lesser-studied member of the RTK family, potentially thwarting solid tumor growth. The compound limits growth in human cancer cells and reduces tumor size in mice.
A Canadian Medical Association Journal study has found genetic variants associated with diseases and adverse drug reactions in 56 healthy participants. The results suggest that whole genome sequencing can benefit Canada's health care, but also highlight potential pitfalls and the need for careful evaluation.
A new study reveals how basal cell cancer responds to treatment and offers new ideas for controlling this disease. The researchers found that the relative location of a cell within a tumor can have a big effect on its sensitivity to drug treatment.
Researchers at the University of Tokyo developed a blood vessel-on-a-chip technology that recreates a human blood vessel and shows how new capillaries grow from a single vessel. The technology can be used to develop drugs targeting angiogenesis, which is a key process in cancer growth.
Researchers at Georgetown University Medical Center used a novel approach to find that the FDA-approved drug clofarabine can shut down Ewing sarcoma cells in lab tests. The study suggests that clofarabine may be effective in treating this rare and aggressive cancer, which primarily affects young people.
Researchers at Osaka University have developed a computational method that reveals chemoresistance drug targets by integrating gene expression level and DNA methylation modification data. The approach identifies TRAF4 as an important gene for chemoresistance in gastrointestinal cancer, including esophageal cancer.
The Data Science Institute at Columbia has awarded grants to five research teams to use data science to solve societal problems in cancer research, medical science, transportation and technology. The teams will work together to transform several fields throughout the university.
A team of scientists from the National University of Singapore has developed a way to wirelessly deliver light into deep regions of the body to activate light-sensitive drugs for photodynamic therapy (PDT). The technology enables PDT to be used on inner organs with fine control, potentially treating a wider range of cancers.
Huntsman Cancer Institute has been selected as a NCI Center for patient-derived model development, utilizing cutting-edge research to test new drugs and drug combinations for breast cancer. The goal is to provide data to prioritize clinical trials and help determine why certain drugs work for some people and others do not.
Researchers have found that PD-1 inhibitors can be effective in treating supratentorial pediatric ependymoma, a type of brain cancer with poor prognosis. The study identified RELA-fusion as a genetic cause and showed that these tumors express high levels of PD-L1, which can be targeted by PD-1 inhibitors.
A recent study presented at the American Stroke Association's International Stroke Conference found that cancer patients with stroke are less likely to receive standard clot-busting medication compared to those without a malignancy. The use of newer procedures to mechanically remove clots, however, shows a similar trend in both groups.
Cancer researchers have identified CDK12 inhibitors as a potential treatment option for Ewing sarcoma, a rare and aggressive childhood cancer. The inhibitors show promise in killing Ewing sarcoma cells and can be combined with PARP inhibitors to increase effectiveness. This breakthrough brings hope to the pediatric oncology field, whic...
Researchers at Queen Mary University of London have successfully modified a common flu virus to target and kill pancreatic cancer cells. The new technique could potentially become a promising new treatment for patients with the aggressive disease.
Researchers have made significant progress in treating non-small cell lung cancer (NSCLC) with the development of molecularly targeted therapies and immunotherapies. These treatments aim to attack tumor cells with mutated genes, but resistance is a common challenge.
A study published in British Journal of Clinical Pharmacology analyzed herbal product interactions with prescription medications. The analysis revealed significant adverse drug reactions, particularly among patients taking warfarin and statins for cardiovascular complications.
A panel of experts has issued new guidelines for molecular diagnostic testing and treatment decisions in lung cancer. The updates reflect recent advancements and decades of work to identify the genetic underpinnings of lung cancer, helping oncologists match patients with effective therapies.
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers. The compounds were tested on micro-tumors and showed effectiveness against specific cancers, giving hope for developing new drugs to fight cancer.
The foundation awarded grants to early career scientists with 'high-risk/high-reward' ideas who lack preliminary data, aiming to significantly impact cancer prevention, diagnosis, and treatment. The recipients will use prebiotics to manipulate the microbiota, develop novel degraders for targeted therapies, and investigate tumor T cells...
Scientists have revealed the atomic-level structure of a molecular complex responsible for modifying proteins, which could lead to new medications for cancer and other diseases. The complex, known as OST, plays a key role in protein glycosylation, a process linked to numerous human body functions.
The study provides the first atomic description of the herpes virus associated with Kaposi's sarcoma, allowing scientists to identify specific targets for antiviral therapies. This breakthrough could lead to the development of new treatments for both KSHV and Epstein-Barr viruses.
Researchers have identified a new precision medicine approach for metastatic pancreatic cancer, analyzing tumor RNA to match patients with targeted drugs. The approach has shown clinical responses in three of four patients, targeting 'master regulator proteins' responsible for cancer cell survival.
Scientists from King's College London have discovered a new drug combination that effectively awakens the immune system to attack cancer. The breakthrough involves combining chemotherapy with a drug trialled for neonatal jaundice, which targets an enzyme called Heme Oxygenase-1 (HO-1) and promotes tumour growth.
Researchers used Cryo-EM to capture images of molecular machinery called RNA Polymerase III in unprecedented detail, revealing five key stages in which the complex reshapes itself to successfully transcribe the DNA code. This discovery could open up new approaches to cancer treatment by targeting the complex's activity.
A randomized controlled trial found that systematic bright light exposure improved sleep efficiency and self-reported sleep quality in fatigued cancer survivors. The intervention showed significant effects compared to dim light exposure.
The NHS bowel scope screening programme saw a significant increase in uptake when patients were sent additional reminders addressing common concerns, highlighting the importance of patient information and support., Bowel cancer is the 4th most common cancer in the UK, with over half of cases diagnosed at a late stage.
RAS molecules act in pairs, known as dimers, to cause cancer and transmit signals that tell a cell to grow and divide. The study provides a foundation for further studies on RAS biology and could potentially pave the way to develop new cancer drugs.
Researchers found that activating REV-ERB proteins can starve cancer cells by blocking nutrient production, while normal cells are not affected. The discovery sheds light on a new uncharacterized way to treat cancer with limited toxicity.
A recent study by Queen Mary University of London found that protein markers are a more accurate predictor of patient responses to midostaurin, a new leukemia treatment. This breakthrough could lead to double the number of patients being treated and improve outcomes for those with acute myeloid leukemia.
Researchers have identified MED1 as a key player in HER2-driven breast cancer development and spread. The study found that mutating MED1 disrupted its interaction with the estrogen receptor, significantly delaying tumor growth and cancer stem-like cell formation.
A study found that new treatments and screening methods have reduced breast cancer deaths by 49% since 2012, compared to 37% in 2000. The reduction is largely due to advances in treatment, with screening contributing 31-48% depending on the molecular subtype.
A recent study by USC researchers found that survival among adolescents and young adults with cancer has not improved over the past three decades. The study breaks down cancer survival rates by race, ethnicity, age group, socioeconomic status, and cancer stage, highlighting disparities in health outcomes.
The UC Santa Cruz Genomics Institute's Treehouse Childhood Cancer Initiative has received a $500,000 grant to conduct a 24-month registry study evaluating the effectiveness of comparative RNA-seq analysis in pediatric cancer treatment. The project aims to assess the impact on clinical decision-making and patient outcomes.
Manning's research focuses on the role of retinoblastoma protein in regulating chromosome segregation. Her work aims to understand how defects in this process contribute to genetic variability and chemotherapy resistance in tumors. The study may lead to new targets for anti-cancer medications.
Researchers at Tel Aviv University discovered an inverse correlation between a known oncogene and tumor suppressant, leading to extended survival rates in pancreatic cancer patients. A novel nanoparticle delivery system selectively targets cancer cells, rendering them dormant or eradicating the tumor altogether.
Researchers have discovered that experimental diabetes drugs can make cancer cells more vulnerable to traditional chemotherapy agents. The combination of carboplatin and one of the experimental compounds, SR1664, sensitized lung tumor cells and triple-negative breast cancer cells in laboratory models, leading to reduced tumor growth.
The new guidelines provide strategies for including patients with brain metastases in clinical trials, addressing the lack of data on drug effects in the brain. The approach includes three specific strategies based on initial understanding of a drug's possible activity in the brain.
A new study from the University of Pennsylvania School of Medicine found that 18% of multiple myeloma patients experiencing cardiovascular adverse events (CVAE) such as hypertension, heart failure, or arrhythmia. Higher doses of carfilzomib are associated with higher rates of CVAE, and the drug is linked to an elevated risk of CVAE com...
A University of Hawaii Cancer Center researcher has identified a mechanism that drives cancer cells to move during metastasis. The study defines a signaling hub required for cancer cell movement, which may provide new therapeutic opportunities for brain tumors and other cancers.
Researchers developed a mathematical model that simulates tumor growth and predicts response to cancer drugs. The model uses parameters of tumor growth to forecast treatment effectiveness, potentially leading to new strategies for predicting tumor response.
A new USC study reveals that tumor growth properties can influence response to cancer drugs. Researchers found certain parameters of tumor growth can forecast the effectiveness of anti-angiogenic treatment, allowing for more accurate predictions. This breakthrough has the potential to improve cancer therapy outcomes.
A new class of medicines called HIF-2a inhibitors, including PT2385, have shown promise in treating metastatic kidney cancer. The drug blocked tumor growth for at least 4 months in 40% of patients and stopped cancer growth for over a year in 25% of patients with minimal side effects.
Researchers at Harvard Medical School have discovered a novel therapeutic strategy to treat drug-resistant thyroid cancers by combining vemurafenib with palbociclib, a CDK4/6 inhibitor. The treatment was shown to induce stronger cell death than when used alone, offering new hope for patients with papillary thyroid carcinoma.
Researchers developed an algorithm using smartphone data to detect worsening symptoms in cancer patients, allowing for early intervention and improved quality of life. The study enrolled 14 patients undergoing chemotherapy treatment, showing 88% accuracy in identifying high-symptom days.
A study found that high out-of-pocket costs for oral cancer medications lead to prescription abandonment, even among those with insurance. Patients faced with costs over $2,000 were more likely to abandon their prescriptions, highlighting the need for strategies to improve patient access.
A new study led by Johns Hopkins Medicine researchers found that tumors with high mutational burden are more likely to respond to checkpoint inhibitors, a class of cancer immunotherapy drugs. The study suggests that precision medicine could be used to guide clinical trials and improve treatment outcomes for specific patient populations.
A recent study published in Oncotarget found that cancer drug affordability is correlated with wealth, with the US having the highest average monthly price per patented drug. This has led to a financial burden on both society and patients, with individuals diagnosed with cancer being 2.7 times more likely to declare bankruptcy.
Scientists have successfully packaged a cancer drug into sperm cells, which were then guided to cervical cancer cells using magnetic forces. The loaded sperm killed over 80% of the cancerous tumor with minimal payload loss.